Survey Defines Patient Preferences in BCMA-Directed T-Cell Engagers

Patients with triple-class-exposed (TCE) relapsed or refractory multiple myeloma considered factors such as overall survival (OS), infections, hospitalization, and off-the-shelf availability to be important when considering B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies, according to an online survey.

The survey data were presented by Sikander Ailawadhi, MD, of the Mayo Clinic, at the Society of Hematologic Oncology 2024 Annual Meeting in Houston, Texas. The survey analysis included 200 patients (43% female; 46% White; 10% African American) with a mean age of 61 ± 6.4 years.

Dr. Ailawadhi and colleagues calculated conditional relative importance (CRI) for the following attributes: objective response rate (ORR), OS, all-grade cytokine release syndrome (CRS), all-grade immune effector cell–associated neurotoxicity syndrome (ICANS), serious infections, treatment administration, and hospitalization requirements.

Based on the discrete choice experiment, the most important attribute was OS (CRI, 32.0% for a 24-month increase), followed by rates of serious infection (CRI, 17.3% for 60% lower risk), hospitalization requirements (CRI, 15% for avoiding a 14-day hospitalization), and ORR (CRI, 13.7% for a 38% increase).

When OS was increased from 12 to 36 months, the estimated maximum acceptable risks for serious infections, CRS, and ICANS were >60%, >95%, and >20%, respectively.

“Therapy decisions for relapsed or refractory multiple myeloma should consider tradeoffs between these attributes,” Dr. Ailawadhi concluded.

Reference

Ailawadhi S, Inocencio TJ, Mansfield C, et al. Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies. Abstract #MM-378. Presented at the Society of Hematologic Oncology Annual Meeting; September 4-7, 2024; Houston, Texas.